Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 in relapsed or refractory extranodal NK/T cell lymphoma (nasal type)
CTR20201122Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Oct 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of reozalimab in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Innovent Biologics. Started Oct 2020; status: terminated.
02
Drugs
reozalimab
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on CTR20201122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201122.